Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
EchoStar Corporation
ECHO·Communication Services
D ★Strong Sell
Current$101.19
Nov 10, 2026

EchoStar's spectrum monetization and stronger liquidity create asset-value recovery potential, but weak recurring cash generation, restructuring obligations, and uncertain transaction economics threaten shareholder returns.

Score
50
Peabody Energy Corporation
BTU·Energy
D ★Strong Sell
Current$16.03
Nov 7, 2026

Peabody offers cyclical recovery potential through low valuation multiples and metallurgical coal exposure, but persistent Centurion disruptions, negative free cash flow, and declining U.S. thermal-coal demand undermine the investment case.

Score
50
Martin Marietta Materials, Inc.
MLM·Materials
D ★Strong Sell
Current$518.15
Nov 7, 2026

Martin Marietta owns a defensible aggregates franchise with long-term pricing power and an expanded specialty minerals platform, but elevated acquisition debt, diluted earnings, and demanding normalized valuation threaten shareholder returns.

Score
50
Neogen Corporation
NEOG·Healthcare
D ★Strong Sell
Current$12.00
Oct 13, 2026

Neogen's established food safety franchise offers meaningful turnaround potential through manufacturing efficiencies and stronger recurring consumable sales, but high leverage and demanding cash-flow valuation leave little room for execution setbacks.

Score
50
Delta Air Lines, Inc.
DAL·Industrials
D ★Strong Sell
Current$80.11
Oct 13, 2026

Delta's premium travel franchise and loyalty economics support long-term cash generation, but elevated fuel costs, earnings downgrades, and limited historical valuation upside weaken the near-term investment case.

Score
50
AST SpaceMobile, Inc.
ASTS·Technology
D ★Strong Sell
Current$36.62
Nov 12, 2026

AST SpaceMobile could become a major global satellite broadband provider through its proprietary technology and carrier partnerships, but heavy cash consumption, shareholder dilution, and demanding valuation threaten investment returns.

Score
49
CG Oncology, Inc.
CGON·Healthcare
D ★Strong Sell
Current$73.74
Nov 10, 2026

CG Oncology's promising bladder cancer immunotherapy and substantial cash reserves offer meaningful clinical upside, but its demanding pre-commercial valuation, accelerating cash burn and shareholder dilution create significant investment risk.

Score
49
Disc Medicine, Inc.
IRON·Healthcare
D ★Strong Sell
Current$78.91
Nov 8, 2026

Disc Medicine's successful bitopertin Phase 3 trial and deep hematology pipeline offer substantial long-term potential, but its premium valuation, pre-commercial losses, regulatory dependence, and dilution create significant investment risk.

Score
49
Comstock Resources, Inc.
CRK·Energy
D ★Strong Sell
Current$13.41
Nov 7, 2026

Comstock's Haynesville gas resources and proposed $1.65B asset monetization offer recovery potential, but persistent negative free cash flow, commodity-price exposure, and debt pressure undermine its current investment appeal.

Score
49
BETA Technologies, Inc.
BETA·Industrials
D ★Strong Sell
Current$24.05
Nov 6, 2026

BETA Technologies offers differentiated electric aircraft technology and a growing commercial backlog, but extreme revenue-based valuation multiples, negative free cash flow and certification risks limit its near-term investment appeal.

Score
49
Noble Corporation plc
NE·Energy
D ★Strong Sell
Current$47.45
Oct 30, 2026

Noble's high-specification offshore drilling fleet and $6.70B backlog offer recovery potential, but weak free cash flow, declining returns on capital and demanding valuation limit its current investment appeal.

Score
49
Vail Resorts, Inc.
Current$138.99
Oct 2, 2026

Vail Resorts owns a scarce, moaty global ski-resort network with strong cash generation, but falling pass demand, weather-sensitive visitation, high leverage and a premium peer valuation make the current setup unusually demanding.

Score
49